Results 91 to 100 of about 3,864 (165)

Editorial: Real-world experience with CFTR modulator therapy

Frontiers in Pharmacology, 2023
Burkhard Tümmler, Burkhard Tümmler, Pierre-Régis Burgel, Pierre-Régis Burgel   +3 more
doaj   +1 more source

Mejoría de la inflamación intestinal tras tratamiento con moduladores de la proteína CFTR en pacientes con fibrosis quística

Anales de Pediatría
Resumen: Introducción: Los tratamientos con moduladores de la proteína CFTR han mejorado la salud respiratoria y digestiva de los pacientes con fibrosis quística.
Ruth García Romero, Concepción López Cárdenes, Elena Crehuá Gaudiza, Marina Álvarez Beltrán, Mercedes Murray Hurtado, Carlos Tutau Gómez, Inés Loverdos Eseverri, Encarni Torcuato Rubio, Camila García Volpe, Enrique Salcedo Lobato, María Medina Martínez, Carmen Martin Fernández, Ana Moreno Álvarez, Ana Reyes Domínguez, David González Jiménez   +14 more
doaj   +1 more source

Cystic Fibrosis Care in South Africa: Facing the Challenge of Diversity and Inequality

Pediatric Pulmonology, Volume 60, Issue 10, October 2025.
ABSTRACT Low‐and‐middle‐income countries (LMIC) like South Africa (SA) were left behind with advancements in cystic fibrosis (CF) care that followed re‐imbursement agreements in high‐income countries of CF transmembrane regulator protein modulators (CFTRm) for the treatment of CF.
Marco Zampoli, Cathy Baird, Brenda Morrow, Janine Verstraete, Greg Calligaro, Mark Seale   +5 more
wiley   +1 more source

Improvement of intestinal inflammation after treatment with CFTR modulators in cystic fibrosis patients

Anales de Pediatría (English Edition)
Introduction: Treatments with CFTR protein modulators have improved respiratory and digestive health in patients with cystic fibrosis. Objective: To assess changes in intestinal inflammation through the analysis of fecal calprotectin in patients with ...
Ruth García Romero, Concepción López Cárdenes, Elena Crehuá Gaudiza, Marina Álvarez Beltrán, Mercedes Murray Hurtado, Carlos Tutau Gómez, Inés Loverdos Eseverri, Encarni Torcuato Rubio, Camila García Volpe, Enrique Salcedo Lobato, María Medina Martínez, Carmen Martin Fernández, Ana Moreno Álvarez, Ana Reyes Domínguez, David González Jiménez, Saioa Vicente Santamaría, Ana Tabares González, Jose Ramon Gutierrez Martinez, Sara Sierra San Nicolás, Pilar Ortiz Pérez, Luis Peña Quintana   +20 more
doaj   +1 more source

Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score

Frontiers in Pharmacology, 2023
Jochen G. Mainz, Jochen G. Mainz, Carlos Zagoya, Louise Polte, Lutz Naehrlich, Lutz Naehrlich, Lenny Sasse, Olaf Eickmeier, Christina Smaczny, Anton Barucha, Lilith Bechinger, Franziska Duckstein, Ludwik Kurzidim, Ludwik Kurzidim, Patience Eschenhagen, Laura Caley, Daniel Peckham, Daniel Peckham, Carsten Schwarz   +18 more
doaj   +1 more source

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Cystic Fibrosis Liver Tests in a Real-World Cohort with and Without Baseline CFLD [PDF]

, 2021
Megan E. Bowen, E. Sample, Ashley Collins, A. Singhal, Alison Brown   +4 more
openalex   +1 more source

Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Decreasing Severe Cystic Fibrosis-Related Exacerbations in Specialty Pharmacy Patients and Vulnerable Subgroups: A Retrospective, Pre-Post Study

, 2022
Christian Rhudy, Lauren Kormelink, Brittany Taylor, Sarah Hegnauer, Elizabeth Autry, Matthew Zeltner, Thom Platt   +6 more
openalex   +1 more source

Elexacaftor/tezacaftor/ivacaftor in children aged ≥6 years with cystic fibrosis heterozygous for F508del and a minimal function mutation: results from a 96-week open-label extension study [PDF]

Children; Cystic fibrosis; MutationNens; Fibrosi quística; MutacióNiños; Fibrosis quística; MutaciónBackground: Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was efficacious and safe in children aged 6-11 years with cystic fibrosis (CF) heterozygous for
Chilvers, Mark, Dittrich, Anna-Maria, Gartner, Silvia, Legg, Julian, Mall, Marcus, Wainwright, Claire   +5 more
core   +1 more source

Structural changes in lung morphology detected by MRI after modulating therapy with elexacaftor/tezacaftor/ivacaftor in adolescent and adult patients with cystic fibrosis [PDF]

, 2023
Valentina Fainardi, Kaltra Skenderaj, Andrea Ciuni, Gianluca Milanese, Michela Deolmi, Francesco Longo, Cinzia Spaggiari, Nicola Sverzellati, Susanna Esposito, Giovanna Pisi   +9 more
openalex   +1 more source

WS12.6 Maternal and foetal outcomes following elexacaftor-tezacaftorivacaftor use during pregnancy and lactation

, 2021
Jennifer L. Taylor‐Cousar, Ravi Jain
openalex   +1 more source